TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Editorial
Keywords: nurse, follow-up services, .
This article has 0 comments
Europe's nurses: an untapped resource
Ambulatory care services are coming under huge pressure from the steady rise in the number of cancer patients who require long-term follow-up. Facilities are overcrowded, staff overstretched, and extended clinic waiting times are becoming the norm. Patients’ physical, emotional and social welfare are often overlooked because there is not enough time to explore their needs and find solutions. It all adds up to a miserable experience for patients and huge frustration for health professionals.
» Kathy Redmond
Evidence has emerged over the past few years that nurse-led clinics may offer one answer to this growing problem. Across a number of cancer types and treatment settings, follow-up by specially trained nurses has been shown to be as effective as follow-up by doctors. Giving nurses the lead role results in similar outcomes, is acceptable to patients and their families and is associated with better symptom management and improved quality of life. Importantly, it is alsomore cost-effective than conventional follow up approaches. These results have been shown to be valid not just for patients requiring ongoing observation following treatment, but also for patients who have just undergone surgery, and those still going through radiotherapy or taking long term treatment.Nurse-led follow-up services can be organised in different ways. Most research to date has been done in a hospital-based ambulatory care setting. A Dutch study recently showed that, following surgery for oesophageal or gastric cancer, regular home visits by specialist nurses is as effective as physician follow-up in an outpatient clinic. Home visits by specialist nurses have been the norm for many years in the palliative care setting. A third potential model is for nurses to do follow-up by telephone, which can be very convenient for patients – especially those who have to travel long distances for a check-up.
Proper training is, of course, critical for ensuring the safety and effectiveness of nurse-led services, and the nurses should have clear protocols to work to and easy access to a physician when they need advice. Given the heterogeneity in cancer nursing practice across Europe, not every country will currently be in a position to find specialist nurses capable of taking responsibility for patient follow-up. But with ambulatory services creaking under the strain, nurses represent an underutilised resource that could offer enormous benefits.
All countries should be thinking about how and where nurse-led follow-up services could be set up, for the benefit of patients, and a more efficient and cost effective health service.
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.






